ArticleCancer management and research2026
Synergistic Inhibition of Angiogenesis and Tumor Progression by CD73 Inhibitor and Menstrual Blood Stem Cell-Derived Exosomes via miR-422a Upregulation in HER2-Positive Breast Cancer.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational techniques to study breast cancer scaffolds for antiangiogenesis: a review.Journal of molecular modeling · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: HER2-positive breast cancer (HER2+ BC) remains an aggressive subtype with limited treatment efficacy due to therapeutic resistance and systemic toxicities. CD73, an ectoenzyme producing extracellular adenosine, promotes tumor progression by enhancing angiogenesis, immune evasion, and metastasis. Exosomes derived from menstrual blood mesenchymal stem cells (Exo-Mens) exhibit anti-tumor and anti-angiogenic effects through bioactive cargo delivery. This study investigated the synergistic therapeutic potential of CD73 inhibition (using APCP) combined with Exo-Mens in HER2+ BC, with particular focus on their effects on angiogenesis-related pathways and on the regulation of miR-20a and miR-422a. Materials and Methods: SKBR3 HER2+ BC cells were treated with Exo-Mens, APCP, and their combination. Exosomes were isolated and characterized by TEM, DLS, and Western blotting. Cytotoxicity assays determined IC Results: APCP showed higher cytotoxic potency (IC Conclusion: The combination of APCP and Exo-Mens demonstrated synergistic anti-tumor effects in HER2+ BC cells by targeting pathways related to angiogenesis, proliferation, and apoptosis. In this context, the upregulation of miR-422a suggests a potential tumor-suppressive role, warranting further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.